Roth Keeps Ligand (LGND) at Buy; BD Indication for Promacta is Pleasant Surprise
Tweet Send to a Friend
Roth Capital reiterates its Buy rating and $69 price target on Ligand Pharmaceuticals (Nasdaq: LGND) following news that partner GlaxoSmithKline ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
